argenx SE (ARGX)
| Market Cap | 61.95B +57.0% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 36.12 |
| Forward PE | 28.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 668,753 |
| Open | 927.33 |
| Previous Close | 851.29 |
| Day's Range | 925.62 - 1,002.16 |
| 52-Week Range | 650.01 - 1,002.16 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 1,082.38 (+9.57%) |
| Earnings Date | Jul 23, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $1,082.38, which is an increase of 9.57% from the latest price.
News
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
ARGX Looks 31.4% Undervalued on GF Value⢠After Positive Vyvgart Trial Data
William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path
William Blair notes that Argenx (ARGX) announced top-line results from the Phase III ALKIVIA trial of Vyvgart in autoimmune myositis, showing a clinically meaningful and statistically significant bene...
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Maintains Overweight Rating, Price Target Raised to $1215 by Piper Sandler
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%
ARGX Looks 31.4% Undervalued on GF Value⢠as Stock Surges 16.6%
ARGX Looks 32.0% Undervalued on GF Valueâ¢
ARGX Looks 32.0% Undervalued on GF Valueâ¢
Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results
Argenx SE stock was up 15.25% on Monday after the company posted results from its ALKIVIA Phase 3 study.
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients wit...
Argenx's Vyvgart Scored Another Win — Why Shares Bolted Higher
Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases.
argenx SE Transcript: Study update
The ALKIVIA phase III trial of VYVGART in autoimmune myositis met its primary endpoint, showing significant and sustained efficacy in both IMNM and DM, with a favorable safety profile. Regulatory submissions are planned for IMNM, and discussions are ongoing for DM, supporting expansion into rheumatology.
argenx SE Press release: Study update
argenx SE issued a press release on August 17, 2026, disclosing material business information to investors.
argenx SE Slides: Study update
argenx SE has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
ARGX Looks 41.1% Undervalued on GF Valueâ¢
ARGX Looks 41.1% Undervalued on GF Valueâ¢
Argenx price target raised to $1,215 from $1,075 at Piper Sandler
Piper Sandler raised the firm’s price target on Argenx (ARGX) to $1,215 from $1,075 and keeps an Overweight rating on the shares. With Q2 2026 reporting wrapped up, the firm…
Argenx price target raised to $1,215 from $1,075 at Piper Sandler
Piper Sandler raised the firm’s price target on Argenx (ARGX) to $1,215 from $1,075 and keeps an Overweight rating on the shares. With Q2 2026 reporting wrapped up, the firm…
ARGX Looks 41.1% Undervalued on GF Value⢠as Phase 3 Trial Boosts Growth Prospects
ARGX Looks 41.1% Undervalued on GF Value⢠as Phase 3 Trial Boosts Growth Prospects
Argenx announces ALKIVIA study meets primary endpoint
Argenx (ARGX) announced topline results from the ALKIVIA Phase 3 study evaluating Vyvgart Hytrulo in adults with autoimmune myositis.In the combined immune-mediated necrotizing myopathy and dermatomyo...
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Zai Lab and Argenx announce results from Alkivia Phase 3 study
Zai Lab (ZLAB) and argenx (ARGX) announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune my...
Argenx announces ALKIVIA study meets primary endpoint
Argenx (ARGX) announced topline results from the ALKIVIA Phase 3 study evaluating Vyvgart Hytrulo in adults with autoimmune myositis.In the combined immune-mediated necrotizing myopathy and dermatomyo...
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Pha...
Argenx announces ALKIVIA study meets primary endpoint
Argenx (ARGX) announced topline results from the ALKIVIA Phase 3 study evaluating Vyvgart Hytrulo in adults with autoimmune myositis.In the combined immune-mediated necrotizing myopathy and dermatomyo...
ARGX Looks 41.1% Undervalued on GF Value⢠After Vyvgart Phase 3 Success
ARGX Looks 41.1% Undervalued on GF Value⢠After Vyvgart Phase 3 Success